Detalhe da pesquisa
1.
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.
Future Oncol
; 19(6): 463-471, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37083162
2.
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Br J Haematol
; 191(3): e77-e81, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32805058
3.
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.
JMIR Cancer
; 8(3): e39068, 2022 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36136395
4.
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.
PLoS One
; 17(5): e0267979, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35550641
5.
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Clin Lymphoma Myeloma Leuk
; 22(9): e836-e843, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643855
6.
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Clin Cancer Res
; 27(10): 2742-2754, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602684
7.
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
Blood Cancer J
; 10(8): 81, 2020 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32769965
8.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Leuk Res
; 88: 106283, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31790983
9.
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
Leuk Lymphoma
; 61(8): 2012-2015, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378440